Search
-
What worries the world - August 2023
Inflation has now been the top global concern in our What Worries the World survey for the last 17 months. However, worry about rising prices has declined for three months in a row, having dropped 3pp from June.
-
Majority of Britons think it is likely Keir Starmer will become Prime Minister
The latest Ipsos Political Pulse reveals that 56% think it is likely that Keir Starmer will be Prime Minister in the future
-
AI is making the world more nervous
One in three workers expect AI to lead to the loss of their current job.
-
Brits want to fight climate change, but a third of consumers unaware of how to make homes greener
New research from Mitsubishi Electric and Ipsos reveals consumers want to support the environment, and there is growing consumer appetite for heat pump technology. It also finds a fundamental lack of understanding around energy efficiency, and underlines the need for the government to prioritise Net Zero awareness.
-
Global views on abortion
A majority across 29 countries believe abortion should be legal in at least most cases.
-
National Student Survey 2023 results released
The National Student Survey (NSS) conducted by Ipsos reaches an overall response rate of 71.5% with over 339,000 students expressing their views in 2023.
-
Fees and student debt are main reasons that quarter of Brits don’t think it’s worth going to university
Research from Ipsos evaluates the main factors putting Brits off from going to university.
-
3 in 5 Britons would prefer utilities to be publicly owned and operated
By contrast, 23% think utilities should be owned and operated privately according to a new Ipsos survey.
-
Six in ten people in England would keep the Green Belt as it is
Retaining the Green Belt should come before meeting housing needs according to a new Ipsos survey for The Economist, but sentiment is based on wildly inaccurate perceptions of the extent to which England has been built on.
-
Oncology: the disease, dynamics & challenges of market research
The oncology treatment landscape rarely stands still, and its constant evolution affects all those involved – from patients and their carers to cancer treaters to the companies who manufacture and market treatments.